Navigation Links
European Society of Human Genetics urges caution over use of new genetic sequencing techniques
Date:5/16/2013

The use of genome-wide analysis (GWA), where the entirety of an individual's DNA is examined to look for the genomic mutations or variants which can cause health problems is a massively useful technology for diagnosing disease. However, it can also pose major ethical problems if used incorrectly, say new recommendations from the European Society of Human Genetics (ESHG) published on line today (16 May 2013) in the European Journal of Human Genetics.

Many services based on whole genome and on exome* sequencing and analysis are now available to patients at an affordable price, and this raises the question of how to ensure that they are provided appropriately. "Such sequencing generates huge amounts of information that needs to be processed, analysed, and stored in a responsible manner", said Professor Martina Cornel, chair of the Professional and Public Policy Committee of ESHG. "It is preferable to use sequencing or analysis specifically targeted at a particular health problem to avoid unsolicited findings, or those that cannot yet be interpreted, which can cause considerable anxiety to patients and their families. Clear guidance on how to deal with such findings is needed."

Targeted analysis will limit such unsolicited findings, says the ESHG, and this is particularly important at present when there are only a limited number of clinicians properly trained to inform patients on the significance of the results of GWAs and exome sequencing. While the Society believes that the duty to inform patients may outweigh their right not to know in some circumstances, the new recommendations propose that analysis should be limited to genome regions linked to the clinical problem for which the analysis is being undertaken.

"We are opposed to the type of opportunistic screening that throws up large numbers of incidental results. If such results reveal a treatable or preventable condition, then clearly it is advantageous to patients to be informed about them.

But in the majority of cases it is very difficult to interpret exactly what such incidental results mean for patients and their families. The evidence currently available often comes from families with affected persons, but it is lacking on the interpretation of results in other situations. Furthermore, in genetics healthcare, autonomy is considered very important: patients should be allowed consent on what would be screened for and reported to them. We believe that it is premature today to look for such results other than the clinical problem in circumstances where there are no prior clinical indications or family history ", said Professor Cornel.

"A sustained effort to educate clinicians in genetics is needed in order to be able to cope with advances in analysis. We also believe that the Society has an important role to play in raising awareness of genetics among the general public. Only with the benefit of a general increase in genetic literacy can society become properly involved in the debate over who has the right to know what and in which circumstances," she said.

Professor GertJan van Ommen, Editor in Chief of the European Journal of Human Genetics, said: "The importance of this issue has been underlined by the US Government's Bioethics Advisory Panel's plans to report on how incidental findings encountered in genomics research should be handled. I believe that ESHG has made an important contribution to the debate, which will be further discussed at their conference in Paris in June."


'/>"/>

Contact: Mary Rice
mary.rice@riceconseil.eu
European Society of Human Genetics
Source:Eurekalert

Related biology news :

1. Core for Life, a new European alliance in biomedical research
2. European support for the first network of research and training in political ecology
3. 8 M € from EU to enhance access by scientists to the largest European biobanks
4. Scientists awarded £3M to study the way Northwest European seas absorb carbon
5. European Guidance for the diagnosis & management of osteoporosis in postmenopausal women
6. Can a tropical water flea invade European lakes?
7. Less than 1 month to start of European Congress on Osteoporosis & Osteoarthritis in Rome
8. A European invader outcompetes Canadian plants even outside its usual temperature range
9. Felix Goñi, Avanti award for best European research in lipids
10. 2013 General Assembly of the European Geosciences Union
11. REACH news: European ombudsman takes up PETA complaint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- Vigilant Solutions announces today that an agency used its ... lead in a difficult homicide case. The agency then used ... suspect vehicle. Due to the ongoing investigation, the agency name ... the agency,s request. --> --> ... found deceased at an intersection here in the City. He ...
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, ... 2014. More than 1,600 participants have joined the PROMPT study, which seeks to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging biopharmaceutical company ... disease, announced today it has been selected to present at the Cavendish Global Health ... Beach, Florida. The purpose of the Forum is to help family offices and ...
(Date:2/9/2016)... 2016  Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to ... recently reported the Company,s operating results for 2015 ... Lonza America , Inc. (the "Lonza ... in the process of consummating an agreement to ...
Breaking Biology Technology: